Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Immunotherapy, especially immune checkpoint inhibitors (ICIs), improves survival rates in advanced melanoma but can impact health-related quality of life (HRQoL) due to induced toxicities[Buhrer2024]. There is limited literature on HRQoL for melanoma patients on ICIs, particularly in observational studies, highlighting the need for more real-world data.
Source: EJC Skin Cancer
Authors: F. Crespí-Payeras, E. Coz, M. Luque-Luna, A. Fournier, M. Gracia-Rius, P. Iglesias, S. Podlipnik, C. Carrera, J. Malvehy, S. Dalle, D. Maucort-Boulch, S. Puig
Institutions: Instituto de Salud Carlos III, Centre for Biomedical Network Research on Rare Diseases, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Lyon 1 Université, Centre National de la Recherche Scientifique, Université de Lyon, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Hospital Clínic de Barcelona, Centre de Recherche en Cancérologie de Lyon
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409118017